Group 1: Historical Price Trends - Historical price trends of commodities follow a sequence: precious metals, industrial metals, petrochemicals, and agricultural products[9] - Since 1970, there have been five significant commodity bull markets, defined by a price increase of over 50%[10] - The typical price increase sequence occurs in less than one quarter for precious metals, about two quarters for petrochemicals, and approximately one quarter for agricultural products[12] Group 2: Current Market Dynamics - Current market dynamics are influenced by domestic industrial transformation and global political changes[28] - Commodities closely tied to traditional industries, such as real estate, are expected to perform poorly due to reduced demand elasticity[30] - Emerging economies are expected to drive future demand growth, with a decoupling from developed economies observed[30] Group 3: Price Increase Pathways - The current price increase is characterized by external rather than internal factors, focusing on two main lines: industrialization in emerging economies and geopolitical tensions affecting import prices[43] - The first main line involves price increases driven by industrialization in emerging economies, which is expected to continue due to China's support[44] - The second main line is influenced by geopolitical risks, which can directly threaten commodity prices and create cost transmission effects[44] Group 4: Investment Outlook - The report is optimistic about the price outlook for the chemical and agricultural sectors while being conservative about commodities closely related to the real estate chain[44] - Risks include market performance falling short of expectations, insufficient pricing of geopolitical risks, and potential underperformance in industry development[45]

Investment Rating - The report maintains a "Positive" outlook on the defense and military industry [4]. Core Insights - The report emphasizes the acceleration of the large aircraft sector and commercial aerospace, driven by the strategic goals set by the Aviation Industry Corporation of China (AVIC) during its 2026 work conference [9][12]. - The competition for low Earth orbit satellite resources is intensifying, with countries like Germany and Japan advancing their satellite communication systems, which is expected to boost China's satellite networking progress [15][16]. - The "14th Five-Year Plan" is set to enhance military equipment construction, highlighting the potential for growth in both domestic and international military markets, particularly in unmanned systems and commercial aerospace [16]. Summary by Sections 1.1 AVIC's 2026 Work Conference - The conference outlined three strategic tasks: accelerating the independent development of aviation engines, achieving high-level technological self-reliance, and building a strong aviation nation [12]. - The focus is on developing five pillar industries: commercial power, general aviation power, civil gas turbines, system onboard, and advanced materials manufacturing services [12][14]. 1.2 Competition in Space Resources - Germany is deploying a domestic "Starlink" system to ensure national security and communication sovereignty, with potential contracts worth billions of euros [15]. - The report notes that China's satellite internet development is entering a rapid networking phase, with over 100 satellites already in orbit [15][16]. 1.3 Continued Optimism for Various Sectors - The report highlights the importance of the military sector's internal and external demand, focusing on new combat capabilities and the expansion of military trade markets [16]. - Key investment targets include companies involved in large aircraft, commercial aerospace, and military electronics, with specific recommendations for stocks such as AVIC Power (600893), AVIC Aircraft (600372), and Aerospace Electronics (600879) [16].

Investment Rating - The report maintains a "Positive" outlook on the power equipment and new energy industry [6] Core Viewpoints - The "14th Five-Year Plan" period saw slower-than-expected carbon reduction, prompting high-energy-consuming industries to accelerate carbon reduction commercialization during the "15th Five-Year Plan" period, leading to a growth inflection point for green fuels [3][8] - The demand for energy storage is expected to grow significantly, with a forecasted 50% increase in energy storage installations by 2025, driven by the rapid growth of new energy [3][19] - The offshore wind power, perovskite, and space photovoltaic sectors are anticipated to exhibit high growth potential during the "15th Five-Year Plan" period [3][8] Summary by Sections 1. Wind and Solar Power Entering Maturity with High Growth in Sub-markets - The demand for new energy installations in China is expected to remain robust, with a target of 360 million kilowatts of wind and solar power capacity by 2035 [12] - The average annual installation space for wind and solar power is projected to exceed 400 GW from 2026 to 2035 [12][13] 2. Energy Storage and Nuclear Power with Stable Supply Attributes - By the end of 2025, China's energy storage installations are expected to reach 66.43 GW, with a year-on-year growth of 52% [19] - The construction speed of nuclear power is expected to accelerate, with a target of 70 million kilowatts of operational capacity by 2025 [21] 3. Carbon Reduction Goals and the Emergence of Green Fuels - The actual carbon reduction progress during the "14th Five-Year Plan" is expected to fall short of the target, necessitating increased efforts in the "15th Five-Year Plan" [26] - Policies are encouraging the integration of green electricity with hydrogen, ammonia, and zero-carbon parks [29] 4. New Photovoltaic Technologies and Nuclear Fusion - Perovskite technology is expected to achieve mass production during the "15th Five-Year Plan" period, with efficiency improvements anticipated [32] - The BEST project aims for completion by 2027, with significant investment expected in nuclear fusion technology [34]

汽车与零部件行业 行业研究 | 行业周报 行业调整下建议关注出海及布局 AI 应用领 域的强α汽零公司 核心观点 投资建议与投资标的 从投资策略上看，预计部分强α汽零公司有望抵御行业风险，实现营收及盈利增长；高 级别自动驾驶产业链、数据中心液冷产业链及能确定进入特斯拉、Figure、智元、宇树等 机器人配套产业链的汽零将持续迎来催化，具备竞争力的自主品牌及在智驾技术方面领 先的企业将继续扩大市场份额。建议持续关注液冷产业链、人形机器人链、出海链、智 驾产业链公司。 机器人相关标的：新泉股份、拓普集团、银轮股份、岱美股份、三花智控、浙江荣泰、 旭升集团、嵘泰股份、斯菱智驱、爱柯迪、精锻科技、博俊科技、沪光股份；液冷相关 标的：英维克、银轮股份、拓普集团、飞龙股份、川环科技等；智驾相关标的：经纬恒 润、伯特利、德赛西威等。 风险提示 宏观经济下行影响汽车需求、上游原材料价格波动影响、车企价格战压力。 国家/地区 中国 行业 汽车与零部件行业 报告发布日期 2026 年 02 月 01 日 中性（维持） | 姜雪晴 | 执业证书编号：S0860512060001 | | --- | --- | | | jiangx ...

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on TCM and high-end generic drugs. The revenue from TCM has historically contributed over 50% of total revenue, while the share of chemical drugs has increased from 24% in 2016 to 36% in 2024 [13][16]. - The company launched an employee stock ownership plan in 2024 to incentivize core personnel, focusing on performance assessment and innovative drug development [23][24]. 2. Innovative Product Data and Growth Potential - The company has several innovative products entering commercialization or late-stage clinical trials. Notably, RAY1225, a dual-target drug for obesity and diabetes, has shown superior efficacy in clinical trials compared to existing treatments [27][29]. - ZSP1601, a first-in-class drug for NASH, is currently in IIb phase clinical trials and has demonstrated promising results in reducing liver inflammation markers [45][49]. 3. Core TCM Products and Market Recovery - The company's core TCM product, Compound Thrombus Tong Capsule, has maintained a leading market share in the ophthalmic TCM sector. As the impact of centralized procurement diminishes, sales are expected to stabilize and recover [9][18]. - The Brain Thrombus Capsule, another key product, has shown stable clinical demand and is projected to continue its steady growth [9][18].

Economic Indicators - The Manufacturing PMI for January 2026 is at 49.3%, falling below the expansion threshold of 50.1%[7] - The Production and New Orders PMI are recorded at 50.6% and 49.2% respectively, both showing significant declines from previous levels[7] Sector Performance - High-tech manufacturing PMI stands at 52%, slightly down from 52.5%, but remains near the second-highest level since the implementation of equal tariff policies in April 2025[7] - The construction sector's activity has slowed significantly, with the PMI dropping below 40% due to adverse weather and the upcoming holiday[7] Demand Dynamics - New Orders PMI has seen a year-on-year decline, marking the second-lowest drop for this period, indicating insufficient domestic demand[7] - New Export Orders PMI decreased by 1.2 percentage points to 47.8%, influenced by prior export surges and trade policy adjustments from key partners[7] Price Trends - Major raw material purchase price index and factory price index have risen to 56.1% and 50.6% respectively, indicating a return to expansion after 20 months[7] - Prices in the non-ferrous metal sector are driving overall price increases, while sectors with weak internal demand, like wood processing, show price contraction[7] Future Outlook - The report suggests that geopolitical changes and investment demand in technology will continue to drive global capital expenditure and commodity prices, particularly in non-energy commodities[7] - The ongoing contradiction of strong supply versus weak demand in the domestic market remains a critical issue, with the ability of upstream prices to transmit to downstream still uncertain[7]

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 23.37 CNY based on a PE valuation of 57 times for 2026 [3][6]. Core Insights - The company is expected to benefit from a dual-driven strategy of traditional Chinese medicine (TCM) and chemical drugs, with a gradual clearance of the impact from centralized procurement on TCM business. The innovative drug pipeline is entering a harvest phase, with projected net profits for 2025-2027 being 290 million, 350 million, and 410 million CNY respectively, corresponding to EPS of 0.34, 0.41, and 0.48 CNY [3][9]. Summary by Sections 1. Dual-Driven Strategy of TCM and Chemical Drugs - The company has a rich product layout and maintains stable performance, with a focus on eye care, cardiovascular, respiratory, and digestive diseases. Revenue for the first three quarters of 2025 was 1.89 billion CNY, a decrease of 1.0% year-on-year, while net profit attributable to the parent company was 250 million CNY, an increase of 68.4% [13][9]. - The core TCM product, Compound Thrombus-Relieving Capsule, is a unique original formulation with a leading market share in the domestic ophthalmic TCM sector. The impact of centralized procurement is gradually being digested, and sales are expected to stabilize [9][10]. 2. Innovative Product Data and Growth Potential - The company has multiple innovative products entering commercialization or late-stage clinical trials. The PB2-targeted RNA polymerase inhibitor, Anladiwei Tablets, was approved in May 2025 for treating adult uncomplicated influenza, showing competitive advantages over Oseltamivir [9][27]. - The GLP-1/GIP dual-target drug RAY1225 for obesity and diabetes has entered Phase III clinical trials, with promising results indicating better weight loss efficacy compared to existing treatments [27][29]. 3. Financial Forecast and Investment Recommendations - The company’s revenue is projected to recover, with expected revenues of 2.803 billion, 3.126 billion, and 3.447 billion CNY for 2025, 2026, and 2027 respectively, reflecting growth rates of 13.6%, 11.5%, and 10.3% [5]. - The report emphasizes the importance of innovation and performance assessment, with an employee stock ownership plan launched in 2024 to incentivize core personnel [23][24].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 107.20 CNY, based on a projected average PE of 40 times for comparable companies in 2026 [4][7]. Core Insights - The company is actively enhancing its robotics layout and accelerating global expansion, indicating a strong commitment to growth in the robotics sector [2][10]. - The company has signed a strategic cooperation agreement with Kaidi Co., aiming to enter the robotics key components market, leveraging both companies' strengths [10]. - The seating and overseas business segments are expected to be significant profit growth drivers, with plans for H-share listing and increased investment in the Mexican factory reflecting confidence in overseas demand [10]. Financial Forecasts - The projected net profit attributable to the parent company for 2025-2027 is expected to be 1.037 billion, 1.366 billion, and 1.746 billion CNY respectively, with corresponding year-on-year growth rates of 6.2%, 31.7%, and 27.8% [4][6]. - Revenue forecasts for 2025-2027 are 17.429 billion, 21.783 billion, and 26.006 billion CNY, with growth rates of 31.4%, 25.0%, and 19.4% respectively [6][10]. - The company's gross margin is projected to be 17.8% in 2025, 17.6% in 2026, and 18.0% in 2027, while the net margin is expected to be 6.0%, 6.3%, and 6.7% for the same years [6][10].

Investment Rating - The report maintains a "Positive" investment rating for the computer industry, indicating an expectation of returns exceeding the market benchmark by more than 5% [3][9]. Core Insights - The server CPU supply from Intel and AMD is constrained, leading to a projected price increase of 10%-15% due to surging demand from customers like CSPs. The production capacity for server CPUs is essentially sold out for the year 2026 [4]. - The price increase is driven by limited advanced process capacity and unexpectedly high downstream demand, particularly as the general server market enters a significant upgrade cycle and AI demand continues to exceed expectations [4]. - The report suggests that the current price increase for server CPUs reflects a structural shift in demand rather than a short-term fluctuation, with expectations for continued growth in both quantity and performance requirements for CPUs [4]. - Domestic CPU manufacturers are expected to benefit from this supply-demand imbalance, with companies like Haiguang Information and Loongson expected to fill the demand gap as domestic cloud service providers accelerate evaluations of domestic alternatives [4]. Summary by Sections Investment Recommendations and Targets - Recommended stocks include Haiguang Information (688041, Buy), Zhongke Shuguang (603019, Buy), and others, as they are positioned to benefit from the supply constraints faced by Intel and AMD [2]. Industry Dynamics - The report highlights a significant shift in the AI landscape, where the demand for high single-core performance and memory bandwidth is becoming critical due to the rise of AI agents and reinforcement learning applications [4]. - The infrastructure focus is expected to shift from "GPU compute power" to "CPU scheduling," indicating a long-term trend in the industry [4].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 107.20 CNY, based on a projected average PE of 40 times for comparable companies in 2026 [4][7]. Core Insights - The company is actively enhancing its robotics layout and accelerating global expansion, indicating a strong commitment to growth in the robotics sector [2][10]. - The company has signed a strategic cooperation agreement with Kaidi Co., aiming to enter the robotics key components market, leveraging both companies' strengths [10]. - The seating and overseas business segments are expected to become significant profit growth drivers, with plans for H-share listing and increased investment in the Mexican factory reflecting confidence in overseas demand [10]. Financial Forecasts - The projected net profits for 2025-2027 are 1.037 billion, 1.366 billion, and 1.746 billion CNY, respectively, with corresponding year-on-year growth rates of 6.2%, 31.7%, and 27.8% [4][6]. - Revenue forecasts for 2025-2027 are 17.429 billion, 21.783 billion, and 26.006 billion CNY, with growth rates of 31.4%, 25.0%, and 19.4% [6][10]. - The company's gross margin is expected to be 17.8% in 2025, 17.6% in 2026, and 18.0% in 2027, while the net margin is projected to be 6.0%, 6.3%, and 6.7% for the same years [6][10]. Valuation Metrics - The company’s PE ratio is projected to decrease from 47.0 in 2023 to 21.7 in 2027, indicating an improving valuation over time [6][11]. - The PB ratio is expected to decline from 7.6 in 2023 to 3.7 in 2027, reflecting a more attractive valuation as earnings grow [6][11].